Clinical Trials & Research

n/a

A011202:

Rand Ph III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Br Ca Pts (CT1-3N1) who have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

ECOG-ACRIN EA1131:

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

ALLIANCE A011401:

Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

S1207:

Ph III Rand, Placebo-Controlled Trial Evaluating Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Pts w/ High-Risk, Hormone Receptor-Positive & HER2/NEU Negative Breast Cancer

NRG-BR003:

Rand Ph III Trial of Adjuvant Therapy Comparing Doxorubicin + Cyclophosphamide Followed by Weekly Paclitaxel w/ or w/o Carboplatin for Node-Positive or High-Risk Node-Negative Triple Negative Invasive Breast Cancer

NRG-BR004:

A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

A011104:

Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer

A211601:  Evaluation of Mammographic Breast Density Effect of Aspirin: A Companion to Alliance Study A011502

A171601:  A Phase II Trial Assessing the Tolerability of Palbociclib in Combination with Letrozole or Fulvestrant in Patients Aged 70 and Older with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer

S1418:  A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy

NRG-GI002:

A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer

S0820: Double-Blind Placebo-Controlled Trial of Eflornithine & Sulindac to Prevent Recurrence of High Risk Adenomas & Second Primary Colorectal Cancers in Pts w/ Stage 0-III Colon or Rectal Ca, Ph III- Preventing Adenomas of the Colon w/ Eflornithine & Sulindac (PACES)

A021502: Randomized Trial of Standard Chemotherapy Alone or
Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III
Colon Cancer and Deficient DNA Mismatch Repair

None

NRG GOG-0238:

A Randomized Trial of Pelvic Irradiation with or Without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus

NRG RTOG-0724:

Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy

n/a

NHLBI-MDS:

The National Myelodysplastic Syndromes (MDS) Study

A151216:

Adjuvant Lung Cancer Enrichment Marker Identification & Sequencing Trial (ALCHEMIST) **Screening trial for A081105, E4512, & EA5142**

A081105:

Rand, Double-Blind, Placebo-Controlled Study of Erlotinib or Placebo in Pts w/ Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant NSCLC **Must be enrolled on screening trial A151216**

E4512:

Ph III Double-Blind Trial for Surgically Resected Early Stage NSCLC: Crizotinib Vs. Placebo for Pts w/ Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein **Must be enrolled on screening trial A151216**

EA5142:

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers **Must be enrolled on screening trial A151216**

LUNGMAP:

A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

none

DCP-001:

Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)

S1609:

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

EAQ162CD:  Longitudinal Assessment of Financial Burden in Patients with Colon or Rectal Cancer Treated with Curative Intent

NCI 10231:  NCORP Tissue Procurement Protocol: An NCI Cancer Moonshot Study

S1415CD:

A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia-Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)

A221602:  OlanzapineWith or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nauseaand Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC):
A Phase III Randomized, Double Blind, Placebo-Controlled Trial

None